会員登録
ログイン
【130A】Veritas In Silico
mRNA を標的とする低分子創薬および核酸創薬のプラットフォーム事業
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025.12 | 2025/11/11 | Q3予 | - | - | - | - | -397 | → | 0.0% | -343.6% | -391 | → | 0.0% | -330.0% | -394 | → | 0.0% | -334.5% |
| 2025.12 | 2025/10/14 | 修正予 | 91 | - | - | - | -397 | ↓ | -343.6% | -343.6% | -391 | ↓ | -330.0% | -330.0% | -394 | ↓ | -334.5% | -334.5% |
| 2025.12 | 2025/08/04 | Q2予 | - | - | - | - | 163 | → | 0.0% | 0.0% | 170 | → | 0.0% | 0.0% | 168 | → | 0.0% | 0.0% |
| 2025.12 | 2025/05/09 | Q1予 | - | - | - | - | 163 | → | 0.0% | 0.0% | 170 | → | 0.0% | 0.0% | 168 | → | 0.0% | 0.0% |
| 2025.12 | 2025/02/13 | 当初予 | - | - | - | - | 163 | - | - | - | 170 | - | - | - | 168 | - | - | - |
| 2024.12 | 2025/02/13 | 実 | - | - | - | - | -212 | ↓ | -247.2% | -247.2% | -233 | ↑ | +0.9% | -282.0% | -236 | ↑ | +0.8% | -318.5% |
| 2024.12 | 2024/12/13 | 修正予 | 189 | ↓ | -72.0% | -72.0% | - | - | - | - | -235 | ↓ | -283.6% | -283.6% | -238 | ↓ | -320.4% | -320.4% |
| 2024.12 | 2024/11/13 | Q3予 | - | - | - | - | 144 | → | 0.0% | 0.0% | 128 | → | 0.0% | 0.0% | 108 | → | 0.0% | 0.0% |
| 2024.12 | 2024/08/05 | Q2予 | - | - | - | - | 144 | → | 0.0% | 0.0% | 128 | → | 0.0% | 0.0% | 108 | → | 0.0% | 0.0% |
| 2024.12 | 2024/05/07 | Q1予 | - | - | - | - | 144 | → | 0.0% | 0.0% | 128 | → | 0.0% | 0.0% | 108 | → | 0.0% | 0.0% |
| 2024.12 | 2024/02/13 | 当初予 | 676 | - | - | - | 144 | - | - | - | 128 | - | - | - | 108 | - | - | - |
| 2023.12 | 2024/02/13 | 実 | 360 | - | - | - | 37 | - | - | - | 35 | - | - | - | 33 | - | - | - |
